Bufexamac
| Autor: | G. S. Avery, R. M. Pinder, T. M. Speight, R. N. Brogden, Phyllis R. Sawyer |
|---|---|
| Rok vydání: | 1975 |
| Předmět: |
medicine.medical_specialty
Administration Topical Skin Absorption Pharmacology toxicology Anti-Inflammatory Agents Dermatitis Bufexamac Pharmacology Hydroxamic Acids Pharmacotherapy Psoriasis medicine Humans Pharmacology (medical) skin and connective tissue diseases Hydrocortisone Wound Healing Relative efficacy business.industry Cream base medicine.disease Fluorinated steroids Dermatology Kinetics business medicine.drug |
| Zdroj: | Drugs. 10:351-356 |
| ISSN: | 0012-6667 |
| DOI: | 10.2165/00003495-197510050-00005 |
| Popis: | Bufexamac2 is a new topically active non-steroidal anti-inflammatory agent incorporated into a cream base for use in eczema and other inflammatory dermatoses. Comparative studies have shown the efficacy of bufexamac 5% cream to be indistinguishable from that of commonly used topical fluorinated corticosteroids in eczema and various other inflammatory dermatoses, but its relative efficacy in psoriasis has yet to be determined. Bufexamac has not been compared with hydrocortisone but it would appear to be at least as effective in eczema (which responds readily to all topical steroids), and is perhaps without the problems associated with long-term or inappropriate use of the more potent fluorinated steroids. It is well tolerated by most patients. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full text from SpringerLink